lipovirtide (LP-80) / Shanxi Kangbao Bio - LARVOL DELTA

Pharmacokinetic and safety evaluation of lipopeptide-based HIV fusion inhibitor Lipovirtide in rats. (PubMed, Antiviral Res) - "Furthermore, LP-80 showed no toxic effects on fertility, embryo-fetal development, or offspring development. Collectively, our studies demonstrate that LP-80 is metabolically stable and exhibits a favorable safety profile, supporting its advancement into clinical trials for HIV treatment."

Journal • PK/PD data • Preclinical • Human Immunodeficiency Virus • Infectious Disease

Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients. (clinicaltrials.gov) - P2 | N=64 | Recruiting | Sponsor: Shanxi Kangbao Biological Product Co., Ltd. | Trial primary completion date: Jun 2024 ➔ Dec 2024

Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients. (clinicaltrials.gov) - P2 | N=64 | Recruiting | Sponsor: Shanxi Kangbao Biological Product Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Human Immunodeficiency Virus • Infectious Disease • CD4

Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients. (clinicaltrials.gov) - P2 | N=64 | Not yet recruiting | Sponsor: Shanxi Kangbao Biological Product Co., Ltd.

New P2 trial • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients (clinicaltrials.gov) - P1 | N=46 | Completed | Sponsor: Shanxi Kangbao Biological Product Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Oct 2021 ➔ Jul 2023 | Trial primary completion date: Aug 2021 ➔ May 2023

Trial completion • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease

Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Shanxi Kangbao Biological Product Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Nov 2022 ➔ Sep 2023 | Trial primary completion date: Oct 2022 ➔ Jun 2023

Trial completion • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Shanxi Kangbao Biological Product Co., Ltd.

New P1 trial • Human Immunodeficiency Virus • Infectious Disease • CD4